FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity
Zurück zur Forschungsbibliothek

Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity

November 20, 2026
Share
Emergierende Forschung

Basiert auf emergierender Forschung. Diese Erkenntnisse sind versprechend, aber erfordern weitere Validierung.

Über diese Analyse

Diese Artikel sind eine AI-basierte Zusammenfassung eines kürzlich veröffentlichten Nachrichtenspieles oder einer klinischen Studienanzeige. Sie sind dazu gedacht, einen schnellen und zugänglichen Überblick für die Peptidforschungscommunity zu bieten. Für vollständige Genauigkeit empfehlen wir immer die unten angegebene Quelle zu überprüfen.

Real-World Study Launches to Track Weight Loss and Well-being After Semaglutide Treatment for Severe Obesity

A new real-world follow-up study has been launched in France to evaluate the long-term impact of semaglutide treatment on individuals with severe obesity. The SEMAFOLLOW study, registered under ClinicalTrials.gov as NCT07423481, aims to gather detailed information about weight trajectories and predictive factors for patients who have undergone treatment with WEGOVY® (semaglutide 2.4 mg). This research is crucial for understanding the effectiveness of peptide therapy in managing severe obesity.

Background

Obesity is a complex condition that affects millions of people worldwide, leading to numerous health complications such as cardiovascular disease and diabetes. In recent years, semaglutide has emerged as an effective treatment option for individuals struggling with weight management. Semaglutide works by mimicking the action of GLP-1 (glucagon-like peptide 1), a hormone that helps regulate blood sugar levels and promotes feelings of fullness.

In France, WEGOVY® is available under temporary authorisation for use (ATU) and an early access programme. This means that patients who meet specific criteria can receive the treatment before it has been fully approved by regulatory bodies like the FDA. The SEMAFOLLOW study seeks to gather data from these real-world settings to provide valuable insights into how semaglutide performs in a broader population.

Key Details

The SEMAFOLLOW study is being conducted by teams of specialists from various obesity centres across France, ensuring a comprehensive evaluation of treatment outcomes. Participants will be followed up over an extended period to track their weight changes, assess the effectiveness of different treatment strategies, and evaluate overall well-being. The study uses the SEMAFOLLOW questionnaire to gather detailed information about patients' experiences with semaglutide.

This research is particularly important because it focuses on individuals with grade 3 obesity (BMI ≥40 kg/m²) or those with obesity-related complications. These patients often face significant challenges in managing their weight and improving their health outcomes, making the findings from this study highly relevant for both clinicians and researchers working in the field of peptide therapy.

Key Takeaways

  • Comprehensive Evaluation: The SEMAFOLLOW study provides a detailed look at how semaglutide performs over time in real-world settings.
  • Patient-Centered Approach: By using the SEMAFOLLOW questionnaire, the study captures the patient's perspective on treatment effectiveness and well-being.
  • Focus on Severe Cases: This research targets individuals with grade 3 obesity or those with severe complications, offering insights that are directly applicable to high-risk patients.
  • Collaborative Effort: The involvement of multiple specialist teams ensures a thorough assessment of semaglutide's impact across different patient populations.

What This Means

For the peptide community, the SEMAFOLLOW study represents an important step forward in understanding the long-term benefits and challenges associated with semaglutide treatment. As more data becomes available from real-world applications, clinicians can make better-informed decisions about which patients might benefit most from this therapy. Additionally, researchers will have valuable information to guide future studies on peptide therapies for obesity management.

The findings from SEMAFOLLOW could also influence regulatory discussions around the approval and use of semaglutide in other regions, including potential FDA regulation updates. This study underscores the importance of ongoing research into peptide-based treatments as a cornerstone of modern weight management strategies.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

Bearbeitungsnotiz

Diese Analyse wurde mit AI-Tools generiert und durch den Peptide Contacts-Bearbeiterteam geprüft. Obwohl wir für die Genauigkeit streben, kann AI-generierter Inhalt Fehler oder Lücken enthalten. Wir ermutigen Leser, die ursprüngliche Quelle für vollständige Details, Methoden und Daten.

Peptide Contacts bietet vercurierte Forschungssummarien zur Informationszwecke an. Dieses Inhalte bilden keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Gesundheitsentscheidungen treffen.

Comments

Sign in to join the discussion

Dieser Artikel wurde mit AI generiert und kann ungenaue Informationen enthalten. Er wird zur Informationszwecke bereitgestellt und bildet keine medizinische Beratung aus. Stets überprüfen Sie die Information mit der ursprünglichen Quelle und beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Gesundheitsentscheidungen treffen.